Cargando…
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer
PURPOSE: Radiation therapy (RT) and hormone receptor (HR) inhibition are used for the treatment of HR-positive breast cancers; however, little is known about the interaction of the androgen receptor (AR) and estrogen receptor (ER) in response to RT in AR-positive, ER-positive (AR+/ER+) breast cancer...
Autores principales: | Michmerhuizen, Anna R., Lerner, Lynn M., Ward, Connor, Pesch, Andrea M., Zhang, Amanda, Schwartz, Rachel, Wilder-Romans, Kari, Eisner, Joel R., Rae, James M., Pierce, Lori J., Speers, Corey W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427858/ https://www.ncbi.nlm.nih.gov/pubmed/35618789 http://dx.doi.org/10.1038/s41416-022-01849-9 |
Ejemplares similares
-
ARe we there yet? Understanding androgen receptor signaling in breast cancer
por: Michmerhuizen, Anna R., et al.
Publicado: (2020) -
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
por: Michmerhuizen, Anna R., et al.
Publicado: (2020) -
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models
por: Michmerhuizen, Anna R., et al.
Publicado: (2022) -
Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models
por: Michmerhuizen, Anna R., et al.
Publicado: (2022) -
RB expression confers sensitivity to CDK4/6 inhibitor–mediated radiosensitization across breast cancer subtypes
por: Pesch, Andrea M., et al.
Publicado: (2022)